banner
Topoisomerase inhibitor, Pirarubicin hydrochloride, Purity ≥98%
Inquiry

Cat. No.: X24-08-YM056

Topoisomerase inhibitor, Pirarubicin hydrochloride, Purity ≥98%

Synonym: 95343-20-7; THP hydrochloride; (7S,9S)-7-[(2R,4S,5S,6S)-4-Amino-6-methyl-5-[(2R)-oxan-2-yl]oxyoxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; hydrochloride

  • CAS Number: 95343-20-7
  • Compound CID: 20846247
img
Product Size
10 mg; 25 mg; 50 mg; 100 mg
Price
Datasheet
MSDS
Properties
Description
Pirarubicin hydrochloride is an effective DNA damage inhibitor, that has the ability to prevent the pathway of DNA damage by inhibiting topoisomerase.
Molecular Weight
664.1
Molecular Formula
C32H38ClNO12
Form
Lyophilized powder
Purity
≥98%
Titer
Free from inappropriate visible particulates, foreign matter, discoloration, or other defects
Applications
Pirarubicin hydrochloride is a DNA damage inhibitor that can be studied extensively for its potential therapeutic applications in the treatment of bladder cancer, leukemia, and breast cancer.
Publications
Publications (0)

Publications

×
Publications

Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.

As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.

*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.

  • You can upload up to 5 images or ZIP files, and the size of a single file may not exceed 5MB.
Related Products
Quick Links

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0